NYKD.OL

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$160365	-79.3%	$-0.07	$-0.09–$-0.06	—	2
2027	$42M	+25846.1%	$0.05	$-8.54–$8.64	—	2
2028	$16M	-62.2%	$-0.03	$-0.03–$-0.02	—	2
2029	$59M	+277.1%	$-0.13	$-0.13–$-0.13	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 4 of the last 6 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-02-25	$-0.20	$-0.25	-23.9%
2025-11-24	$-0.20	$-0.10	+50.2%
2025-08-20	$-0.25	$0.00	+101.1%
2025-05-12	$-0.23	$-0.00	+98.1%
2025-02-26	$-0.54	$-0.24	+55.3%
2024-11-27	$-0.05	$-0.32	-538.9%

DCF fair valuemodel estimate

Intrinsic value

$1.67

Price

$3.82

Implied downside

-56%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
NYKD.OLNykode Therapeutics AS	$3.92	+3.02%	$1.3B	—
ABS.OLArctic Bioscience AS	$2.79	+3.33%	$75M	—
AZT.OLArcticZymes Technologies ASA	$20.70	+0.49%	$1.1B	—
BGBIO.OLBerGenBio ASA	$1.17	+0.00%	$46M	—
CONTX.OLContextVision AB (publ)	$4.70

Nykode Therapeutics AS

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of locally advanced and metastatic tumors; and VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer. Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway.

www.nykode.com

Employees: 59
IPO / List date: Oct 7, 2020
HQ: NO

Held by traders on TradeandTell

No one on the platform currently holds NYKD.OL.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in NYKD.OL as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded NYKD.OL yet.